The faculty open the Between the Lines discussion by framing why advanced biliary tract cancer (BTC) remains a difficult-to-treat malignancy with rising incidence.
The discussion turns to the TOPAZ-1 study design and its long-term efficacy update.
The faculty review patient-reported outcomes, subgroup consistency, and biomarker testing before introducing the second pivotal trial.
The panel reviews the KEYNOTE-966 long-term follow-up data.
The discussion moves to real-world evidence and meta-analysis.
The faculty step back to compare trial data with real-world evidence before reviewing a phase 3b feasibility study.
The faculty synthesize the evidence into clinical positioning and outline the questions that remain open.
